Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
02 Januar 2024 - 12:36PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
January, 2024
Commission
File Number 1-15182
DR.
REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F x Form
40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission
in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer
must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized
(the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities
are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the
registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.
Yes
¨ No
x
If “Yes” is marked, indicate below the file number assigned
to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
DR. REDDY’S LABORATORIES LIMITED (Registrant) |
|
|
|
|
Date: January 2,
2024 |
By: |
/s/ K Randhir Singh |
|
|
Name: |
K Randhir Singh |
|
|
Title: |
Company Secretary |
Exhibit 99.1
|
Dr. Reddy’s
Laboratories Ltd.
8-2-337,
Road No. 3, Banjara Hills,
Hyderabad
- 500 034, Telangana,
India.
CIN :
L85195TG1984PLC004507
Tel :
+91 40 4900 2900
Fax :
+91 40 4900 2999
Email
: mail@drreddys.com
www.drreddys.com |
January 2, 2024
National Stock Exchange of India Ltd. (Scrip Code:
DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/Madam,
Ref: Disclosure
under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
This is to inform that the Company has received
an order from GST Authority towards tax demand including interest and penalty. The details as required under Regulation 30 of SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015 are as hereunder:
Name of the authority |
: |
GST authorities, Office of Assistant Commissioner (CGST), Ahmedabad Gujarat |
Nature and details of the action(s) taken, initiated or order(s) passed |
: |
The Company has received order seeking demand including interest and penalty in respect of Gujarat state under CGST Act, 2017. |
Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority |
: |
Order dated November 07, 2023 was received by the authorized officials of the Company on December 30, 2023. |
Details of the violation(s)/ contravention(s) committed or alleged to be committed |
: |
The authority has passed the order on the contention that the Company has wrongly availed and utilized transitional credit of input tax. |
Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible |
: |
There is no material impact on financials, operations
or other activities of the Company.
Tax – Rs. 41,14,128/-
Interest – As per Section 50 of CGST Act
2017
Penalty – Rs. 8,22,826/- |
The Company will file necessary appeal with the
appellate authority in this regard..
This is for your information and records.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer &
Head-CSR
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
Von Mai 2023 bis Mai 2024